| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 266, Issue 25, 16343-16349, Sep, 1991
Y Laroche, M Demaeyer, JM Stassen, Y Gansemans, E Demarsin, G Matthyssens, D Collen and P Holvoet
Corvas International NV, Ghent, Belgium.
A recombinant single-chain molecule, scFv-K12G0, containing the variable domains of the monoclonal antibody MA-15C5, specific for fragment D-dimer of human cross-linked fibrin, was constructed and expressed in Spodoptera frugiperda, Sf9, insect cells. The Arg108 carboxyl-terminal amino acid of the variable domain of the light-chain of the antibody was connected through a synthetic Ala-Gly-Gln-Gly-Ser- Ser-Val peptide linker with the Gln1 amino-terminal amino acid of the variable domain of its heavy chain. scFv-K12G0 was secreted by the infected Sf9 cells at a rate of 10 micrograms/10(6) cells within 48 h, resulting in conditioned medium with a maximal concentration of 15 mg of scFv-K12G0/liter. The molecule, purified to homogeneity by ion exchange chromatography and gel filtration, migrated as a single Mr band on reduced sodium dodecyl sulfate-gel electrophoresis. It bound to immobilized fragment D-dimer with an affinity constant of 4.0 x 10(9) M- 1 (2.0 x 10(10) M-1 for intact MA-15C5). Clearing of scFv-K12G0 from the circulation in rabbits occurred with an initial half-life (t1/2 alpha) of 10 min and a clearance of 5.1 ml min-1, as compared to 90 min and 210 ml min-1 for intact MA-15C5. Nephrectomy resulted in a prolongation of t1/2 alpha to 110 min, suggesting that the rapid clearance of scFv-K12G0 occurs primarily via the kidney, presumably by glomerular filtration. The results indicate that the single-chain recombinant molecule scFv-K12G0 is secreted in functionally intact form and suggest that it may be useful for targeting of radioisotopes or plasminogen activators to blood clots in vivo.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J.-C. Peter, P. Eftekhari, P. Billiald, G. Wallukat, and J. Hoebeke scFv Single Chain Antibody Variable Fragment as Inverse Agonist of the {beta}2-Adrenergic Receptor J. Biol. Chem., September 19, 2003; 278(38): 36740 - 36747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kang, S. Hamilton, J. Odili, G. Wilson, and J. Kupsch In Vivo Targeting of Malignant Melanoma by 125Iodine- and 99mTechnetium-labeled Single-chain Fv Fragments against High Molecular Weight Melanoma-associated Antigen Clin. Cancer Res., December 1, 2000; 6(12): 4921 - 4931. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. Y. Li, K. Sugimura, R. J.Boado, H. J. Lee, C. Zhang, S. Duebel, and W. M.Pardridge Genetically engineered brain drug delivery vectors: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody–streptavidin fusion gene and protein Protein Eng. Des. Sel., September 1, 1999; 12(9): 787 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. De Jonge, C. Heirman, M. d. Veerman, S. Van Meirvenne, M. Moser, O. Leo, and K. Thielemans In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model J. Immunol., August 1, 1998; 161(3): 1454 - 1461. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
